All Issues
Current Issue

.Reprint (PDF) (229 KB)

Search Pubmed for articles by:

PY Hsu
ML Yeh
CF Huang
CY Dai
ML Yu
JF Huang
WL Chuang

Search Google Scholar for articles by:

PY Hsu
ML Yeh
CF Huang
CY Dai
ML Yu
JF Huang
WL Chuang

International Research Journal of Medicine and Biomedical Sciences
Vol.4 (4),pp. 38-41, October, 2019
ISSN 2488-9032
Available online at https://www.journalissues.org/IRJMBS/
DOI:https://doi.org/10.15739/irjmbs.19.007
Author(s) retain the copyright of this article. Author(s) agree that this article remain permanently open access under the terms of the Creative Commons Attribution License 4.0 International License.



Case Study

Hepatitis B reactivation with hepatic decompensation after the use of direct-acting antiviral agents in a patient with chronic Hepatitis B and C coinfection

Po-Yao Hsu*1, Ming-Lun Yeh1,2, Chung-Feng Huang1,2, Chia-Yen Dai1,2 Ming-Lung Yu1,2, Jee-Fu Huang*1,2,and Wan-Long Chuang1,2

1Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University,Kaohsiung, Taiwan.
2Faculty of Internal Medicine, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

*Corresponding Author Email:u9501067(at)gmail.com, jfliver(at)kmu.edu.tw

Tel.:+886937463502
Tel: +886-7-312-1101
ext. 7475



date Received: August 12, 2019     date Accepted: October 5, 2019     date Published: October 24, 2019


 Abstract

In recent years, direct-acting antiviral agents (DAAs) have become the major therapy for Hepatitis C virus (HCV) infection and chronic Hepatitis C (CHC). However, Hepatitis B virus (HBV) reactivation (HBVr) remains an important issue among patients with HBV/HCV coinfection when receiving DAAs for CHC. The severity of HBVr-induced Hepatitis may range from a mild to a severe form of liver injury. In this study, we present a rare case of HBVr leading to a decompensated state and jaundice in a 72-year-old man during DAA treatment. His decompensated state subsequent to HBVr, fortunately improved after initiating oral antiviral treatment for HBV. Our case highlights the importance of the pretreatment evaluation of patients for HBV, monitoring potential HBVr, and the initiation of HBV antiviral therapy in HBV/HCV coinfected patients.


Key words: Direct-acting antiviral agents, chronic Hepatitis C, Hepatitis B virus reactivation, decompensation.


Hsu et al